BACKGROUND: Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity. METHODS: Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy (26 serial stereotactic biopsy, 2 resection). Expression of differentially expressed genes was validated by real-time PCR. RESULTS: Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status. 176 genes were differentially expressed, 164 being associated with 1p/19q loss (86% not on 1p or 19q). 94 genes differed between responders and non-responders to chemotherapy; 12 were not associated with 1p/19q loss. Significant differential expression was confirmed in 11/13 selected genes. Novel genes associated with response to therapy included SSBP2, GFRA1, FAP and RASD1. IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss. CONCLUSION: Gene expression profiling using serial stereotactic biopsies indicated greater homogeneity within tumors than between tumors. Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
BACKGROUND:Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity. METHODS: Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy (26 serial stereotactic biopsy, 2 resection). Expression of differentially expressed genes was validated by real-time PCR. RESULTS: Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status. 176 genes were differentially expressed, 164 being associated with 1p/19q loss (86% not on 1p or 19q). 94 genes differed between responders and non-responders to chemotherapy; 12 were not associated with 1p/19q loss. Significant differential expression was confirmed in 11/13 selected genes. Novel genes associated with response to therapy included SSBP2, GFRA1, FAP and RASD1. IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss. CONCLUSION: Gene expression profiling using serial stereotactic biopsies indicated greater homogeneity within tumors than between tumors. Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
Authors: Yuanyuan Xiao; Paul A Decker; Terri Rice; Lucie S McCoy; Ivan Smirnov; Joseph S Patoka; Helen M Hansen; Joe L Wiemels; Tarik Tihan; Michael D Prados; Susan M Chang; Mitchel S Berger; Matthew L Kosel; Brooke L Fridley; Daniel H Lachance; Brian Patrick O'Neill; Jan C Buckner; Reid C Thompson; Louis Burt Nabors; Jeffrey J Olson; Steve Brem; Melissa H Madden; James E Browning; John K Wiencke; Kathleen M Egan; Robert B Jenkins; Margaret R Wrensch Journal: Clin Cancer Res Date: 2012-04-03 Impact factor: 13.801
Authors: Nicholas Brian Shannon; Joey Wee-Shan Tan; Hwee Leong Tan; Weining Wang; Yudong Chen; Hui Jun Lim; Qiu Xuan Tan; Josephine Hendrikson; Wai Har Ng; Li Yang Loo; Thakshayeni Skanthakumar; Seettha D Wasudevan; Oi Lian Kon; Tony Kiat Hon Lim; Grace Hwei Ching Tan; Claramae Shulyn Chia; Khee Chee Soo; Chin-Ann Johnny Ong; Melissa Ching Ching Teo Journal: Sci Rep Date: 2019-07-22 Impact factor: 4.379